~~<i id='93301875C6'><strike id='93301875C6'><tt id='93301875C6'><pre id='93301875C6'></pre></tt></strike></i>~~

Home» focus» explore

explore

author：fashion 2025-09-27 11:06:57 Page View：83776

Venture capitalist Alexis Borisy Vanessa Leroy for STAT

EQRx is done, sold for its cash.

The once-buzzy but now dormant biotech company is being acquired by Revolution Medicines, a developer of cancer drugs, the companies announced Tuesday.

The all-stock deal is essentially a balance-sheet transfer of $1 billion in cash from EQRx to Revolution. What was left of EQRx’s drug pipeline is being shelved.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Mass General Brigham physicians react to latest merger step
Next article： DIEP, the 'gold standard' of breast reconstruction, is under threat

explore

Continuity nursing helped my family in our darkest PICU moments

EssayauthorSarahMcCarthycuddleswithherdaughterMolly.CourtesySarahMcCarthyTheventilatoralarmwokemeat3

Young boy dies in trial for Pfizer Duchenne gene therapy

MarkLennihan/APAyoungboydiedinatrialforPfizer’sexperimentalgenetherapyforDuchennemusculardystrophy,t

In Memoriam: Notable people who died in 2023

1:29AlanArkinattendsthe26thAnnualScreenActorsGuildAwardsatTheShrineAuditoriumonJan.19,2020inLosAngel

FDA advisers back CAR

AdobeApanelofexpertadviserstotheFoodandDrugAdministrationonFridayvotedinfavorofexpandingtheuseofCAR-